NCT06397807View on ClinicalTrials.gov

Postoperative Pain Management on Patients Undergoing Lung Tumor Resection

Not yet recruitingOBSERVATIONAL

Enrollment

400

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

March 2, 2026

Study Completion Date

May 30, 2026

Conditions

Postoperative PainLung CancerLung Tumor

Interventions

DRUG

Dinalbuphine sebacate

Dinalbuphine sebacate (DS) is a long-acting injectable. With oil-based formulation, DS will slowly releases to blood vessel and be hydrolyzed to nalbuphine after intramuscularly injection. The analgesic effect lasts around 5 to 7 days.

DRUG

Analgesic injectables

Opioids, NSAIDs or acetamol will be administrated as need.

DRUG

Enteral analgesics

Opioids, NSAIDs or acetaminophen will be prescribed if necessary.

All Listed Sponsors

lead

China Medical University Hospital

OTHER

NCT06397807 - Postoperative Pain Management on Patients Undergoing Lung Tumor Resection | Biotech Hunter | Biotech Hunter